EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Sarepta Therapeutics (SRPT.O) shares dropped nearly 17% in premarket trading after Europe's medicines regulator issued a negative opinion on the approval of its gene therapy, Elevidys, for Duchenne muscular dystrophy. This regulatory setback compounds existing challenges for Sarepta, which has faced increased scrutiny following two patient deaths associated with the treatment, impacting its partnership with Roche (ROG.S) outside the U.S.

Analysis

Sarepta Therapeutics (SRPT) faces a significant regulatory setback after the European medicines regulator issued a negative opinion on the approval of its gene therapy, Elevidys. The market's reaction was immediate and severe, with the company's shares declining nearly 17% in premarket trading. This decision compounds Sarepta's existing challenges, notably the increased regulatory scrutiny following two recent patient deaths linked to the therapy. The negative recommendation not only jeopardizes a major European market opportunity for Elevidys but also casts a shadow over the asset's overall safety and efficacy profile, potentially influencing other regulatory bodies and impacting its partnership with Roche outside the United States. The situation highlights substantial hurdles in the commercialization path for a key product in Sarepta's pipeline.

Key Decisions for Investors

• Investors should re-evaluate Sarepta's revenue forecasts, heavily discounting or removing potential European sales for Elevidys in the near to medium term.
• Monitor for official responses from Sarepta and its partner Roche, as their strategy for addressing the EU regulator's concerns will be critical for the therapy's future.
• Given the heightened regulatory risk and prior safety concerns, consider the increased potential for volatility and downside pressure on the stock until there is a clear path forward in Europe.